Calin Arimie, MD
Gastroenterology · West Hills
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 36 years
- Graduated 1990
Offices
2 locations · Genesis Healthcare Partners PC · 232 clinicians in this group
Hospitals listed: Northridge Hospital Medical Center · UCLA West Valley Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Arimie’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A63334 · Current
Licensed to practise in California · since 1997 · expires 2027-06-30 · Institute of Medicine and Pharmacy in Bucharest.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Specialty Surgical Center of Encino LLC dba Specialty Surgical Center of EncinoAmbulatory Surgery Center · Encino, CA1% owner since 2024 · accredited by AAAHCAccreditation Renewed3 inspections, 2 with deficiencies · last 2025-04-10
- Surgicare of West Hills, Inc.Ambulatory Surgery Center · West Hills, CA.7 owner since 2009 · accredited by AAAHCAccreditation Renewed4 inspections · last 2022-10-26
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Northridge Hospital Medical CenterNorthridge, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.11, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.147, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- UCLA West Valley Medical CenterWest Hills, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 1 of 5 · 53% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.454, Oct 2024 – Sep 2025
See every measure and the patient survey for Northridge Hospital Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.11 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.147 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.173 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.13 to 2.13) · 1,012 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.78 (0.44 to 1.11) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.43 (96.43 to 190.42) · 88 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 216 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 457 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.4 · 384 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 315 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 3,091 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.05 to 0.44) · 6,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 6,139 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,225 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.28 to 3.34) · 1,193 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.26 (0 to 15.07) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.14 (2.11 to 10.16) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.14) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.76) · 5,578 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 139 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 1.041 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 368 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 674 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 27.2 · 214 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.2 · 563 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.8 · 438 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 484 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.1 to 7.4) · 44 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (6.8 to 13.8) · 44 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 166 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.9 · 57 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 141 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 165 cases | No different | Jan 2024 – Dec 2024 |
What patients said (621 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for UCLA West Valley Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.454 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.87 (0 to 1.86) · 925 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.74 to 1.41) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 126.11 (75.24 to 176.99) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 29 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 179 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 310 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.3 · 499 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 187 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.36) · 5,783 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.09 to 0.48) · 5,787 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.94 (1.81 to 6.06) · 1,083 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.83 (0.29 to 3.36) · 1,048 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.62 (6.73 to 22.51) · 354 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.07 (1.14 to 9) · 319 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 221 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1.09) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.457 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.124 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.781 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.838 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 201 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 400 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 5.5 · 173 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.2 · 369 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 51.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 569 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.8 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (9.3 to 17.4) · 30 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 136 cases | No different | Jan 2024 – Dec 2024 |
What patients said (519 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 67% |
| Staff "always" explained | 49% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 78% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 64% |
| Doctors "always" treated them with courtesy and respect | 73% |
| Patients who gave a rating of "9" or "10" (high) | 52% |
| Staff "always" explained new medications | 64% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 74% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 53% |
| Staff "always" explained possible side effects | 35% |
| Yes, staff "did" give patients information about possible symptoms | 81% |
Original Medicare doctor bills
$144,651
Medicare paid this office $144,651 for 444 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 208 | $22,406 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 132 | $20,571 | $62 |
| Return visit (30+ min) | 102 | $15,024 | $97 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 103 | $9,054 | $39 |
| Biopsy of large bowel using a flexible endoscope | 52 | $7,585 | $143 |
See all 18 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 208 | $22,406 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 132 | $20,571 | $62 |
| Return visit (30+ min) | 102 | $15,024 | $97 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 103 | $9,054 | $39 |
| Biopsy of large bowel using a flexible endoscope | 52 | $7,585 | $143 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 102 | $7,469 | $71 |
| Insertion of stomach tube using a flexible endoscope | 39 | $6,343 | $163 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 14 | $6,059 | $41 |
| New patient visit (45+ min) | 46 | $5,718 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,344 | $141 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 22 | $4,585 | $199 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 14 | $4,411 | $52 |
| Short return visit (20+ min) | 43 | $3,495 | $71 |
| New patient visit (30+ min) | 42 | $3,217 | $77 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $2,898 | $132 |
| Diagnostic exam of large bowel using a flexible endoscope | 24 | $2,785 | $111 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $1,976 | $73 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $70 | $5 |
Procedures Medicare counted
| Colonoscopy | 117 | More than 83% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 230 | More than 92% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 107 | 79 | 60 | 84 | 85 | 105 |
| Biopsy of large bowel using a flexible endoscope | 51 | 47 | 30 | 66 | 49 | 53 |
| Insertion of stomach tube using a flexible endoscope | – | 21 | 27 | 20 | 31 | 39 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 17 | 14 | 13 | 19 | 11 | 23 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | – | 15 | 20 | 16 | 27 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | 17 | 11 | 15 | 15 | 22 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
444 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 19% · Women 57% · Also on Medicaid 48% · Health risk score 2.27. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Coronary heart disease 55% · Diabetes 50% · Heart failure 37% · Chronic kidney disease 37% · Depression 37% · Atrial fibrillation 30% · COPD 25% · Dementia 23% · Cancer 22% · Stroke 17%.
The office billed $940,655, Medicare allowed $189,606 and paid $144,651; for 1,783 services of 54 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 444 | 1,783 | 75 | 2.27 | $940,655 | $144,651 |
| 2023 | 369 | 1,411 | 74 | 2.24 | $727,747 | $122,938 |
| 2022 | 356 | 1,364 | 76 | 2.20 | $570,882 | $131,839 |
| 2021 | 312 | 1,141 | 76 | 2.13 | $354,343 | $110,184 |
| 2020 | 300 | 1,260 | 74 | 2.37 | $389,115 | $118,223 |
| 2019 | 338 | 1,220 | 75 | 2.15 | $285,589 | $111,856 |
| 2018 | 357 | 1,310 | 75 | 2.04 | $317,853 | $120,504 |
| 2017 | 381 | 1,515 | 75 | 2.35 | $314,447 | $123,987 |
| 2016 | 317 | 1,081 | 75 | 2.02 | $230,884 | $88,645 |
| 2015 | 372 | 1,389 | 74 | 2.17 | $322,755 | $129,967 |
| 2014 | 304 | 1,066 | 74 | 2.23 | $268,298 | $102,916 |
| 2013 | 314 | 1,006 | 75 | 2.28 | $325,637 | $99,573 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 130 | $29,313 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 161 | $19,676 | $106 |
| Return visit (30+ min) | 117 | $15,974 | $99 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 85 | $6,521 | $77 |
| Biopsy of large bowel using a flexible endoscope | 49 | $6,279 | $128 |
| New patient visit (45+ min) | 50 | $5,479 | $110 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 12 | $5,123 | $41 |
| Insertion of stomach tube using a flexible endoscope | 31 | $4,852 | $157 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 12 | $4,078 | $53 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 14 | $2,588 | $185 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $2,332 | $155 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 11 | $2,155 | $196 |
| Short return visit (20+ min) | 26 | $2,114 | $78 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,764 | $147 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,433 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,383 | $126 |
2022: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 160 | $29,649 | $59 |
| Return visit (30+ min) | 124 | $20,779 | $101 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 159 | $19,115 | $112 |
| Biopsy of large bowel using a flexible endoscope | 66 | $8,855 | $134 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 83 | $7,063 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $5,984 | $162 |
| New patient visit (45+ min) | 46 | $5,672 | $123 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 19 | $4,126 | $217 |
| Insertion of stomach tube using a flexible endoscope | 20 | $3,319 | $166 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $2,385 | $159 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $2,000 | $100 |
2021: 12 services
| Return visit (30+ min) | 132 | $25,397 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 126 | $24,931 | $60 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 92 | $11,171 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $8,791 | $163 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 58 | $5,525 | $92 |
| Insertion of stomach tube using a flexible endoscope | 27 | $4,668 | $173 |
| New patient visit (45+ min) | 34 | $4,441 | $131 |
| Biopsy of large bowel using a flexible endoscope | 30 | $3,587 | $120 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $2,863 | $220 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,599 | $145 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,441 | $96 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $984 | $33 |
2020: 13 services
| Return visit (30+ min) | 149 | $23,700 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 85 | $16,964 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 87 | $12,011 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $11,427 | $176 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 86 | $7,734 | $34 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 74 | $6,244 | $79 |
| Biopsy of large bowel using a flexible endoscope | 47 | $5,924 | $126 |
| New patient visit (45+ min) | 28 | $3,796 | $136 |
| Insertion of stomach tube using a flexible endoscope | 21 | $3,749 | $179 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 14 | $2,892 | $207 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $2,877 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,016 | $92 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,894 | $158 |
2019: 13 services
| Return visit (30+ min) | 145 | $21,665 | $87 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 111 | $12,990 | $33 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 100 | $12,521 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $10,702 | $173 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 101 | $9,849 | $92 |
| Biopsy of large bowel using a flexible endoscope | 51 | $6,594 | $129 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 15 | $6,114 | $408 |
| New patient visit (45+ min) | 46 | $6,072 | $132 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 17 | $3,809 | $224 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $3,725 | $62 |
| Diagnostic exam of large bowel using a flexible endoscope | 11 | $1,789 | $163 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,137 | $103 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 15 | $866 | $54 |
2018: 18 services
| Return visit (30+ min) | 156 | $22,317 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 113 | $14,485 | $114 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 120 | $13,899 | $33 |
| Biopsy of large bowel using a flexible endoscope | 57 | $9,037 | $159 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,876 | $171 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 16 | $6,499 | $406 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 74 | $6,017 | $79 |
| New patient visit (45+ min) | 46 | $5,743 | $125 |
| Removal of stent from pancreatic or bile duct using a flexible endoscope | 11 | $3,635 | $330 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,530 | $62 |
| Insertion of stomach tube using a flexible endoscope | 18 | $3,493 | $175 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 16 | $3,241 | $203 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 15 | $3,042 | $203 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $2,740 | $211 |
| Diagnostic exam of large bowel using a flexible endoscope | 16 | $2,474 | $146 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $2,014 | $168 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,380 | $81 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 17 | $1,121 | $49 |
2017: 14 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 187 | $23,955 | $114 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 174 | $22,980 | $33 |
| Return visit (30+ min) | 130 | $18,833 | $88 |
| Biopsy of large bowel using a flexible endoscope | 61 | $8,962 | $147 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 87 | $8,289 | $90 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 15 | $6,525 | $408 |
| New patient visit (45+ min) | 43 | $5,717 | $133 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 19 | $3,900 | $205 |
| Insertion of stomach tube using a flexible endoscope | 20 | $3,334 | $167 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 12 | $2,443 | $204 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $2,218 | $171 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | $2,117 | $163 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,574 | $98 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 16 | $1,420 | $84 |
2016: 11 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 136 | $16,022 | $110 |
| Return visit (30+ min) | 122 | $15,619 | $82 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 116 | $13,957 | $33 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 71 | $7,225 | $99 |
| Biopsy of large bowel using a flexible endoscope | 38 | $5,332 | $140 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 19 | $3,816 | $201 |
| New patient visit (45+ min) | 31 | $3,806 | $123 |
| Insertion of stomach tube using a flexible endoscope | 16 | $3,013 | $177 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $2,320 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,257 | $60 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $997 | $91 |
2015: 17 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 168 | $22,076 | $115 |
| Return visit (30+ min) | 128 | $20,935 | $90 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 138 | $17,403 | $33 |
| Biopsy of large bowel using a flexible endoscope | 46 | $9,948 | $212 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 88 | $9,408 | $99 |
| New patient visit (45+ min) | 46 | $6,164 | $134 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 23 | $5,729 | $249 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 13 | $5,467 | $421 |
| Diagnostic exam of large bowel using a flexible endoscope | 24 | $4,258 | $177 |
| Control of bleeding of upper large bowel using a flexible endoscope | 12 | $3,954 | $282 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $2,511 | $167 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,463 | $224 |
| Insertion of stomach tube using a flexible endoscope | 13 | $2,382 | $183 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 14 | $1,556 | $86 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,499 | $83 |
| Short return visit (20+ min) | 15 | $1,109 | $58 |
| New patient visit (30+ min) | 11 | $1,033 | $94 |
2014: 17 services
| Return visit (30+ min) | 113 | $18,539 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 116 | $14,070 | $112 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 90 | $9,546 | $32 |
| New patient visit (45+ min) | 45 | $5,788 | $129 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 56 | $5,664 | $96 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 18 | $4,734 | $249 |
| Biopsy of large bowel using a flexible endoscope | 23 | $4,524 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,633 | $60 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $3,486 | $174 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,756 | $162 |
| Insertion of stomach tube using a flexible endoscope | 14 | $2,546 | $182 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,520 | $229 |
| Diagnostic exam of large bowel using a flexible endoscope | 14 | $2,410 | $172 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 12 | $2,270 | $162 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,977 | $94 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $1,100 | $85 |
| Short return visit (20+ min) | 12 | $640 | $53 |
2013: 17 services
| Return visit (30+ min) | 97 | $13,592 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 117 | $12,813 | $108 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 102 | $9,598 | $32 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 14 | $6,400 | $427 |
| Biopsy of large bowel using a flexible endoscope | 31 | $6,119 | $197 |
| New patient visit (45+ min) | 40 | $5,376 | $134 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 46 | $4,707 | $100 |
| Control of bleeding of upper large bowel using a flexible endoscope | 17 | $4,673 | $275 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 15 | $3,836 | $256 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $3,637 | $227 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $3,460 | $59 |
| Insertion of stomach tube using a flexible endoscope | 14 | $2,927 | $209 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,445 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,250 | $161 |
| Incision of pancreatic outlet using a flexible endoscope | 14 | $1,226 | $88 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $900 | $82 |
| Short return visit (20+ min) | 12 | $808 | $62 |
Medicaid work
$2,773 in 2024
Medicaid paid $2,773 for 97 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 60 | $2,333 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 37 | $440 |
| 2024 | 97 | 2 | 16 | $2,773 |
| 2023 | 41 | 1 | 13 | $998 |
| 2022 | 113 | 3 | 16 | $2,904 |
| 2021 | 158 | 2 | 15 | $3,697 |
| 2020 | 79 | 3 | 18 | $1,736 |
| 2019 | 63 | 2 | 17 | $1,955 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 41 | $998 |
2022
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 29 | $1,909 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 44 | $560 |
| Return visit (30+ min) | 40 | $434 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 100 | $3,697 |
| Return visit (30+ min) | 58 | $0 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 48 | $1,640 |
| Return visit (30+ min) | 13 | $96 |
| New patient visit (45+ min) | 18 | $0 |
2019
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 25 | $1,310 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 38 | $645 |
Drugs they prescribed that Part D paid
$176,968
Pharmacies billed $176,968 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 891) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
730 generic and 161 brand-name prescriptions · $176,968 in drug cost · 34 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 111 | $114,534 | $1,032 |
| Omeprazole-Sodium Bicarbonate | 17 | $16,396 | $964 |
| Movantik | 21 | $8,506 | $405 |
| Sod Sulf-Potass Sulf-Mag Sulf | 142 | $8,460 | $60 |
| Mesalamine | 28 | $8,166 | $292 |
See all 15 drugs
| Linzess | 111 | $114,534 | $1,032 |
| Omeprazole-Sodium Bicarbonate | 17 | $16,396 | $964 |
| Movantik | 21 | $8,506 | $405 |
| Sod Sulf-Potass Sulf-Mag Sulf | 142 | $8,460 | $60 |
| Mesalamine | 28 | $8,166 | $292 |
| Lansoprazole | 50 | $2,561 | $51 |
| Omeprazole | 174 | $1,761 | $10 |
| Esomeprazole Magnesium | 51 | $1,297 | $25 |
| Pantoprazole | 41 | $588 | $14 |
| Sucralfate | 28 | $585 | $21 |
| Sulfasalazine | 17 | $500 | $29 |
| Famotidine | 34 | $201 | $6 |
| Ondansetron Odt | 14 | $170 | $12 |
| Prednisone | 13 | $53 | $4 |
| Metronidazole | 12 | $44 | $4 |
Year by year
| 2024 | 891 | 304 | 0% (0) | 18% | $176,968 |
| 2023 | 822 | 296 | 0% (0) | None | $235,325 |
| 2022 | 780 | 290 | None | 37% | $187,732 |
| 2021 | 724 | 236 | 0% (0) | 34% | $234,495 |
| 2020 | 921 | 231 | None | 31% | $267,737 |
| 2019 | 912 | 246 | None | 31% | $222,736 |
| 2018 | 880 | 228 | 0% (0) | 41% | $343,114 |
| 2017 | 799 | 232 | None | 43% | $186,563 |
| 2016 | 865 | 239 | None | 41% | $298,710 |
| 2015 | 790 | 221 | 2% (15) | None | $291,996 |
| 2014 | 654 | 198 | None | 37% | $54,019 |
| 2013 | 662 | 184 | 4% (24) | None | $63,316 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Linzess | 85 | $107,772 | $1,268 |
| Omeprazole-Sodium Bicarbonate | 21 | $57,344 | $2,731 |
| Sod Sulf-Potass Sulf-Mag Sulf | 142 | $11,148 | $79 |
| Mesalamine | 14 | $9,460 | $676 |
| Dexlansoprazole Dr | 15 | $3,800 | $253 |
| Omeprazole | 129 | $2,565 | $20 |
| Lansoprazole | 35 | $2,514 | $72 |
| Suprep | 13 | $1,506 | $116 |
| Pantoprazole | 71 | $1,263 | $18 |
| Esomeprazole Magnesium | 39 | $1,128 | $29 |
| Sucralfate | 24 | $542 | $23 |
| Famotidine | 38 | $432 | $11 |
| Gavilyte-G | 26 | $417 | $16 |
2022: 13 drugs
| Linzess | 51 | $63,878 | $1,253 |
| Suprep | 145 | $16,257 | $112 |
| Mesalamine | 15 | $8,529 | $569 |
| Budesonide Ec | 14 | $6,835 | $488 |
| Esomeprazole Magnesium | 39 | $6,034 | $155 |
| Lansoprazole | 32 | $2,300 | $72 |
| Sod Sulf-Potass Sulf-Mag Sulf | 25 | $2,085 | $83 |
| Omeprazole | 135 | $2,061 | $15 |
| Sucralfate | 34 | $1,416 | $42 |
| Pantoprazole | 74 | $1,139 | $15 |
| Gavilyte-G | 23 | $293 | $13 |
| Famotidine | 17 | $200 | $12 |
| Ondansetron | 25 | $131 | $5 |
2021: 11 drugs
| Linzess | 84 | $84,987 | $1,012 |
| Suprep | 91 | $9,882 | $109 |
| Mesalamine | 14 | $9,797 | $700 |
| Budesonide Ec | 11 | $9,227 | $839 |
| Dexilant | 15 | $6,206 | $414 |
| Esomeprazole Magnesium | 27 | $6,074 | $225 |
| Lansoprazole | 37 | $5,764 | $156 |
| Omeprazole | 155 | $2,329 | $15 |
| Sucralfate | 34 | $1,205 | $35 |
| Pantoprazole | 50 | $750 | $15 |
| Famotidine | 35 | $696 | $20 |
2020: 18 drugs
| Linzess | 93 | $82,607 | $888 |
| Pentasa | 11 | $16,115 | $1,465 |
| Omeprazole-Sodium Bicarbonate | 24 | $15,320 | $638 |
| Dexilant | 27 | $11,895 | $441 |
| Amitiza | 17 | $11,302 | $665 |
| Zenpep | 11 | $10,339 | $940 |
| Suprep | 74 | $7,667 | $104 |
| Esomeprazole Magnesium | 64 | $6,836 | $107 |
| Lansoprazole | 29 | $6,582 | $227 |
| Sucralfate | 34 | $3,302 | $97 |
| Mercaptopurine | 12 | $2,962 | $247 |
| Omeprazole | 213 | $2,773 | $13 |
| Pantoprazole | 44 | $624 | $14 |
| Megestrol Acetate | 12 | $584 | $49 |
| Famotidine | 28 | $365 | $13 |
| Prednisone | 22 | $221 | $10 |
| Metronidazole | 15 | $163 | $11 |
| Levofloxacin | 16 | $101 | $6 |
2019: 18 drugs
| Linzess | 82 | $65,912 | $804 |
| Dexilant | 26 | $12,669 | $487 |
| Budesonide Ec | 17 | $11,260 | $662 |
| Amitiza | 18 | $9,895 | $550 |
| Suprep | 83 | $8,198 | $99 |
| Lansoprazole | 25 | $7,760 | $310 |
| Esomeprazole Magnesium | 72 | $7,652 | $106 |
| Omeprazole | 204 | $2,760 | $14 |
| Balsalazide Disodium | 13 | $2,179 | $168 |
| Mercaptopurine | 15 | $1,671 | $111 |
| Sucralfate | 30 | $829 | $28 |
| Pantoprazole | 35 | $382 | $11 |
| Prednisone | 17 | $267 | $16 |
| Famotidine | 19 | $255 | $13 |
| Gavilyte-G | 17 | $206 | $12 |
| Metronidazole | 15 | $167 | $11 |
| Ranitidine | 20 | $123 | $6 |
| Levofloxacin | 11 | $110 | $10 |
2018: 18 drugs
| Linzess | 128 | $75,130 | $587 |
| Ocaliva | 23 | $73,078 | $3,177 |
| Dexilant | 25 | $10,311 | $412 |
| Amitiza | 12 | $7,362 | $614 |
| Suprep | 70 | $6,468 | $92 |
| Lansoprazole | 19 | $6,227 | $328 |
| Budesonide Ec | 12 | $4,761 | $397 |
| Esomeprazole Magnesium | 33 | $4,480 | $136 |
| Nexium | 18 | $4,403 | $245 |
| Omeprazole | 182 | $2,196 | $12 |
| Moviprep | 17 | $1,725 | $101 |
| Mercaptopurine | 15 | $1,721 | $115 |
| Sucralfate | 22 | $669 | $30 |
| Polyethylene Glycol 3350 | 15 | $532 | $35 |
| Ranitidine | 30 | $364 | $12 |
| Pantoprazole | 43 | $277 | $6 |
| Prednisone | 14 | $139 | $10 |
| Famotidine | 11 | $78 | $7 |
2017: 16 drugs
| Linzess | 86 | $36,183 | $421 |
| Amitiza | 37 | $11,734 | $317 |
| Dexilant | 27 | $10,236 | $379 |
| Suprep | 102 | $9,001 | $88 |
| Nexium | 35 | $8,958 | $256 |
| Esomeprazole Magnesium | 17 | $3,372 | $198 |
| Mercaptopurine | 20 | $1,970 | $98 |
| Omeprazole | 135 | $1,929 | $14 |
| Sucralfate | 28 | $911 | $33 |
| Lansoprazole | 24 | $720 | $30 |
| Polyethylene Glycol 3350 | 12 | $387 | $32 |
| Ondansetron | 14 | $275 | $20 |
| Diphenoxylate-Atropine | 11 | $192 | $17 |
| Metronidazole | 15 | $159 | $11 |
| Pantoprazole | 24 | $132 | $5 |
| Levofloxacin | 15 | $119 | $8 |
2016: 15 drugs
| Linzess | 66 | $24,533 | $372 |
| Amitiza | 46 | $17,968 | $391 |
| Nexium | 40 | $10,415 | $260 |
| Suprep | 110 | $9,123 | $83 |
| Dexilant | 20 | $6,745 | $337 |
| Prevacid | 11 | $4,082 | $371 |
| Omeprazole | 213 | $2,617 | $12 |
| Sucralfate | 47 | $1,441 | $31 |
| Lansoprazole | 42 | $1,147 | $27 |
| Metoprolol | 13 | $297 | $23 |
| Pantoprazole | 33 | $276 | $8 |
| Polyethylene Glycol 3350 | 13 | $245 | $19 |
| Metronidazole | 12 | $163 | $14 |
| Prednisone | 11 | $91 | $8 |
| Levofloxacin | 13 | $79 | $6 |
2015: 16 drugs
| Linzess | 46 | $14,838 | $323 |
| Nexium | 33 | $8,643 | $262 |
| Suprep | 106 | $8,604 | $81 |
| Amitiza | 32 | $8,496 | $266 |
| Lansoprazole | 49 | $2,006 | $41 |
| Omeprazole | 164 | $1,802 | $11 |
| Rabeprazole | 16 | $990 | $62 |
| Sucralfate | 24 | $789 | $33 |
| Ondansetron | 12 | $297 | $25 |
| Pantoprazole | 23 | $260 | $11 |
| Spironolactone | 16 | $214 | $13 |
| Generlac | 13 | $207 | $16 |
| Metronidazole | 13 | $196 | $15 |
| Levofloxacin | 15 | $176 | $12 |
| Famotidine | 11 | $57 | $5 |
| Hydrochlorothiazide | 12 | $48 | $4 |
2014: 15 drugs
| Nexium | 57 | $14,220 | $249 |
| Linzess | 21 | $6,123 | $292 |
| Suprep | 74 | $5,804 | $78 |
| Aciphex | 11 | $3,973 | $361 |
| Dexilant | 19 | $3,507 | $185 |
| Omeprazole | 173 | $2,351 | $14 |
| Rabeprazole | 14 | $1,219 | $87 |
| Lansoprazole | 26 | $893 | $34 |
| Sucralfate | 16 | $581 | $36 |
| Pantoprazole | 30 | $527 | $18 |
| Generlac | 13 | $287 | $22 |
| Metronidazole | 19 | $255 | $13 |
| Levofloxacin | 20 | $218 | $11 |
| Lorazepam | 11 | $190 | $17 |
| Famotidine | 11 | $136 | $12 |
2013: 15 drugs
| Aciphex | 25 | $9,051 | $362 |
| Dexilant | 46 | $8,552 | $186 |
| Nexium | 27 | $6,260 | $232 |
| Amitiza | 14 | $5,260 | $376 |
| Suprep | 65 | $4,730 | $73 |
| Omeprazole | 168 | $3,192 | $19 |
| Lansoprazole | 13 | $1,099 | $85 |
| Pantoprazole | 44 | $1,049 | $24 |
| Sucralfate | 16 | $588 | $37 |
| Generlac | 11 | $271 | $25 |
| Metronidazole | 15 | $254 | $17 |
| Famotidine | 14 | $217 | $15 |
| Levofloxacin | 14 | $158 | $11 |
| Prednisone | 11 | $115 | $10 |
| Tramadol | 22 | $109 | $5 |
Money from drug and device companies
$1,327 in 2025
| 2025 | 8 | 39 | None | $1,327 |
| 2024 | 7 | 34 | None | $1,107 |
| 2023 | 5 | 30 | None | $369 |
| 2022 | 6 | 41 | None | $844 |
| 2021 | 3 | 25 | None | $272 |
| 2020 | 1 | 2 | None | $46 |
| 2019 | 6 | 67 | None | $627 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ardelyx | Ibsrela | $458 | 12 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $247 | 4 payments
|
| Abbvie | Creon | $190 | 14 payments
|
| Janssen Biotech | Tremfya | $181 | 4 payments
|
| Phathom Pharmaceuticals | Voquezna | $150 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $48 | 2 payments
|
See all 39 published payments
| Ardelyx | Meals · 2025-12-10 | Ibsrela | $34 |
| Abbvie | Meals · 2025-11-26 | Creon | $9 |
| Abbvie | Meals · 2025-11-12 | Creon | $23 |
| Abbvie | Meals · 2025-11-04 | Linzess | $10 |
| Ardelyx | Meals · 2025-11-03 | Ibsrela | $34 |
| Abbvie | Meals · 2025-10-30 | Linzess | $25 |
| Novo Nordisk | Meals · 2025-10-23 | Wegovy | $32 |
| Abbvie | Meals · 2025-10-17 | Creon | $9 |
| Madrigal Pharmaceuticals | Meals · 2025-10-16 | Rezdiffra | $41 |
| Ardelyx | Meals · 2025-10-15 | Ibsrela | $7 |
| Abbvie | Meals · 2025-10-07 | Creon | $19 |
| Janssen Biotech | Meals · 2025-09-17 | Tremfya | $10 |
| Ardelyx | Meals · 2025-09-11 | Ibsrela | $34 |
| Abbvie | Meals · 2025-09-09 | Linzess | $4 |
| Abbvie | Meals · 2025-09-09 | Linzess | $1 |
| Janssen Biotech | Meals · 2025-08-28 | Tremfya | $10 |
| Abbvie | Meals · 2025-08-08 | Creon | $9 |
| Ardelyx | Meals · 2025-07-22 | Ibsrela | $33 |
| Abbvie | Meals · 2025-07-16 | Creon | $8 |
| Abbvie | Meals · 2025-07-08 | Creon | $20 |
| Ardelyx | Meals · 2025-07-03 | Ibsrela | $34 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-30 | Xifaxan | $23 |
| Ardelyx | Meals · 2025-06-05 | Ibsrela | $32 |
| Janssen Biotech | Meals · 2025-06-03 | Tremfya | $12 |
| Janssen Biotech | Meals · 2025-05-21 | Tremfya | $148 |
| Ardelyx | Meals · 2025-05-12 | Ibsrela | $35 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-04-21 | Xifaxan | $25 |
| Abbvie | Meals · 2025-04-16 | Linzess | $21 |
| Ardelyx | Meals · 2025-04-07 | Ibsrela | $33 |
| Abbvie | Meals · 2025-03-25 | Creon | $4 |
| Ardelyx | Meals · 2025-03-20 | Ibsrela | $35 |
| Madrigal Pharmaceuticals | Meals · 2025-03-13 | Rezdiffra | $49 |
| Ardelyx | Meals · 2025-02-20 | Ibsrela | $30 |
| Abbvie | Meals · 2025-02-18 | Linzess | $26 |
| Phathom Pharmaceuticals | Meals · 2025-02-04 | Voquezna | $150 |
| Ardelyx | Meals · 2025-01-30 | Ibsrela | $118 |
| Madrigal Pharmaceuticals | Meals · 2025-01-29 | Rezdiffra | $119 |
| Madrigal Pharmaceuticals | Meals · 2025-01-28 | Rezdiffra | $37 |
| Ironwood Pharmaceuticals | Meals · 2025-01-16 | Linzess | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,107
| Janssen Biotech | Tremfya | $512 | 12 payments
|
| Ironwood Pharmaceuticals | Linzess | $198 | 13 payments
|
| Phathom Pharmaceuticals | Voquezna | $125 | 1 payment
|
| Abbvie | Creon | $99 | 4 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $61 | 1 payment
|
| Ardelyx | Ibsrela | $59 | 2 payments
|
| Boston Scientific | Advanix Biliary | $53 | 1 payment
|
2023: $369
| Ironwood Pharmaceuticals | Linzess | $159 | 13 payments
|
| AbbVie | Viberzi | $153 | 14 payments
|
| Janssen Biotech | Stelara | $29 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $15 | 1 payment
|
| Genzyme | Dupixent | $13 | 1 payment
|
2022: $844
| Abbvie | Rinvoq | $271 | 16 payments
|
| Ironwood Pharmaceuticals | Linzess | $175 | 19 payments
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $150 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $138 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $98 | 1 payment
|
| Genzyme | Dupixent | $13 | 1 payment
|
2021: $272
| Ironwood Pharmaceuticals | Linzess | $134 | 14 payments
|
| AbbVie | Humira | $122 | 10 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $16 | 1 payment
|
2020: $46
| AbbVie | Humira | $46 | 2 payments
|
2019: $627
| Allergan | Linzess | $342 | 53 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Plenvu | $155 | 9 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $53 | 1 payment
|
| AbbVie | Humira | $34 | 2 payments
|
| Richard Wolf Medical Instruments | None | $25 | 1 payment
|
| Apollo Endosurgery US | Overstitch | $17 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2022 | Their institution | $80,000 |
| Boehringer Ingelheim International GmbH · Proof of Clinical Principal in Crohn'S Disease · 2024 | Their institution | $62,887 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2024 | Their institution | $59,816 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2020 | Their institution | $57,626 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2021 | Their institution | $42,197 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2025 | Their institution | $33,920 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2019 | Their institution | $28,556 |
| Eli Lilly and Company · A Phase 3 Multicenter Randomized Double-Blind Placebo- and Active- Controlled Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2023 | Their institution | $24,192 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2021 | Their institution | $22,618 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2022 | Their institution | $19,326 |
| Eli Lilly and Company · A Phase 3 Multicenter Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2023 | Their institution | $19,254 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2022 | Their institution | $18,741 |
| Eli Lilly and Company · A Phase 3 Multicenter Open Label Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2023 | Their institution | $17,979 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2020 | Their institution | $16,155 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2020 | Their institution | $15,706 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open Label, Long Term Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease · 2021 | Their institution | $15,289 |
| ABBVIE INC. · A Study To Assess the Change in Disease Activity in Adult Participants With Moderate To Severe Ulcerative Colitis Treated With Risankizumab Compared To Vedolizumab (Revamp) · 2025 | Their institution | $11,690 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Proof of Clinical Principal in Crohn?S Disease · 2023 | Their institution | $9,710 |
| Eli Lilly and Company · A Multicenter, Phase 3b, Open-Label, Single-Arm Study To Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately To Severely Active Ulcerative Colitis Treated With Mirikizumab · 2024 | Their institution | $9,484 |
| Boehringer Ingelheim International GmbH · Proof of Clinical Principal in Crohn?S Disease · 2023 | Their institution | $8,642 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2022 | Their institution | $7,066 |
| Boehringer Ingelheim International GmbH · Proof of Clinical Principal in Crohn?S Disease · 2022 | Their institution | $7,050 |
| Eli Lilly and Company · A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo Or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately To Severely Active Ulcerative Colitis and Obesity Or Overweight · 2025 | Their institution | $5,070 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Proof of Clinical Principal in Crohn?S Disease · 2022 | Their institution | $4,690 |
| Boehringer Ingelheim International GmbH · A Phase Iia, Randomised, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bi 706321 Orally Administered for 12 Weeks in Patients With Crohn`S Disease (Cd) Receiving Ustekinumab Induction Tre · 2025 | Their institution | $4,589 |
| GlaxoSmithKline, LLC. · A Multicentre Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu · 2021 | Their institution | $4,400 |
| Eli Lilly and Company · A Multicenter, Phase 3b, Open-Label, Single-Arm Study To Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately To Severely Active Ulcerative Colitis Treated With Mirikizumab · 2025 | Their institution | $4,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · P3 Ac Vdz To Ada in UC N=658, 2 Arms, US-Eu · 2019 | Their institution | $3,723 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2022 | Their institution | $3,673 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2024 | Their institution | $3,524 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2020 | This clinician | $3,328 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2025 | Their institution | $2,500 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Proof of Clinical Principal in Crohn'S Disease · 2024 | Their institution | $1,765 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2019 | This clinician | $1,592 |
| Eli Lilly and Company · A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo Or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately To Severely Active Crohns Disease and Obesity Or Overweight · 2025 | Their institution | $1,095 |
| Eli Lilly and Company · A Multicenter Phase 3b Open-Label Single-Arm Study To Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately To Severely Active Ulcerative Colitis Treated With Mirikizumab · 2023 | This clinician | $860 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2019 | This clinician | $488 |
| Eli Lilly and Company · A Phase 3, Multicenter, Open-Label Extension Study To Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis Lucent 3 · 2020 | Their institution | $436 |
| Roche Products Limited · Crohn S Disease Program Cohort 1 Induction Cohort II Maintenance · 2022 | Their institution | $340 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2) · 2020 | This clinician | $28 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 1) · 2020 | This clinician | $26 |
| Boehringer Ingelheim Pharma GmbH & Co.KG · Proof of Clinical Principal in Crohn???S Disease · 2025 | Their institution | $9 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1831277847
- Licence
- CA A63334California A63334: Current · expires 2027-06-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 7320 Woodlake Ave, Ste 260, West Hills, CA, 91307
- NPI first listed
- 2006-11-01
- NPI last updated
- 2017-01-17
This is when the NPI record was last certified, not a medical board exam.